

From: Fauci, Anthony (NIH/NIAID) [E]
Sent: Sun, 1 Mar 2020 19:22:37 +0000
To: Cassetti, Cristina (NIH/NIAID) [E]
Subject: FW: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"
Attachments: (0) The Science of Exulta for the Common Cold.pdf, 1) METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VIRAL UPPER RESPIRATORY TRACT INFECTIONS.pdf

Please handle.

Anthony S. Fauci, MD
Director
National Institute of Allergy and Infectious Diseases
Building 31, Room 7A-03
31 Center Drive, MSC 2520
National Institutes of Health
Bethesda, MD 20892-2520
Phone: (b) (6)
FAX: (301) 496-4409
E-mail: (b) (6)

The information in this e-mail and any of its attachments is confidential and may contain sensitive information. It should not be used by anyone who is not the original intended recipient. If you have received this e-mail in error please inform the sender and delete it from your mailbox or any other storage devices. The National Institute of Allergy and Infectious Diseases (NIAID) shall not accept liability for any statements made that are the sender's own and not expressly made on behalf of the NIAID by one of its representatives.

From: Jim Iversen (b) (6)
Sent: Sunday, March 1, 2020 1:53 PM
To: Fauci, Anthony (NIH/NIAID) [E] (b) (6) >
Cc: Jacqueline Iversen (b) (6) >
Subject: Novel Treatment for Reducing Symptoms Associated with Coronavirus (COVID-19) - "Non-Confidential"

Dear Dr. Fauci,

Sen-Jam Pharmaceutical has a product under development to reduce the symptoms associated with Upper Respiratory Infection (URI). We believe it could provide relief to a large number of people during the COVID-19 pandemic. Our product SJP-002 is a combination of an NSAID and a non-sedating antihistamine and does not include a decongestant. Removing the decongestant makes our product ideal for treating the symptoms associated with COVID-19 in patients with cardiac conditions who cannot tolerate taking a decongestant.

What makes our product novel is that it can be administered early in the treatment phase, thereby reducing the excessive accumulation of inflammation, which typically results in head congestion, pulmonary congestion, coughing, & sneezing. Our experience has shown that at the 1st signs of experiencing symptoms of URI an individual's symptoms can be drastically reduced after taking our